Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Codexis
AddedFeb 15, 2024
UpdatedJun 28, 2026
Codexis

Codexis

Public

American firm, Codexis, Inc., engineers proteins for pharmaceutical, food, and medical uses.

HQ
Redwood City, CA, US
Founded
2002
Overview
Compare
Fundraising
Employees
Website

Codexis, Inc., founded in 2002 and headquartered in Redwood City, California, is a public American company specializing in protein engineering. The company's core mission is to develop high-performance enzymes for pharmaceutical, food, and medical applications, leveraging biocatalysis and industrial enzyme technologies. Codexis aims to revolutionize these industries by providing sustainable and efficient solutions that enhance product quality and reduce environmental impact.

Notable figures associated with Codexis include Stephen Dilly, Ph.D. The company is traded on Nasdaq under the ticker CDXS and is a component of the Russell 2000 index. Codexis has achieved significant milestones, including the development of proprietary enzyme products that have been adopted by leading pharmaceutical companies. Its innovative approaches have positioned Codexis as a key player in the protein engineering market, driving advancements in drug development and industrial biotechnology.

Codexis - Quick Facts

When was Codexis founded?

Codexis was founded in 2002.

Where is Codexis' headquarters located?

Codexis' headquarters is located in Redwood City, CA, US.

When was Codexis' last funding round?

Codexis' most recent funding round was for $75M (USD) in December 2020.

How much has Codexis raised to-date?

As of Dec 2, 2020, Codexis has raised a total of $162M (USD).

How many employees does Codexis have?

Codexis has 248 employees as of Feb 6, 2024.

Codexis - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Enzyme Development
Tags
  • Biotech
Unique IDs
  • ein: 710872999
  • secCik: 0001200375
  • ticker: CDXS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2860Industrial Organic Chemicals
  • 2800Chemicals And Allied Products
ISIC
  • 2011Manufacture of basic chemicals
Show 24 more industry codes
NAICS
  • 320000Manufacturing
  • 325100Basic Chemical Manufacturing
  • 325120Industrial Gas Manufacturing
  • 325300Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing
  • 325320Pesticide and Other Agricultural Chemical Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2869Industrial Organic Chemicals, Not Elsewhere Classified
  • 2870Agricultural Chemicals
  • 2879Pesticides And Agricultural Chemicals, Not Elsewhere Classified
  • 2890Miscellaneous Chemical Products
  • 2899Chemicals And Chemical Preparations, Not Elsewhere Classified
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research